ClinicalTrials.gg
RecruitingNCT05388682Updated Sep 22, 2026

Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

An observational study in Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty and PAH Targeted Medication, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational

How we know

From the registry’s dates

  • Started Jan 2014; still recruiting 12 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Takayasu Arteritis with a site in China — 15 open to participants now, 16 under way, 2 of them phase 3. Takayasu Arteritis · China.

Planned enrollment
8th of 11
200 · median 1,000
Started
2014
with 1 other
Observational
11 of 26
7 open now
Primary completion
2042-12
later than 14 of 15 live
Registered
17th of 26
by date
Lead sponsor
2 of 26
Chinese Pulmonary Vascular Disease Research Group

Among the 26 studies in Takayasu Arteritis with a site in China, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2014, is one of 11 observational ones, reaches primary completion later than 14 of the 15 other live ones, and was the 17th registered.

Takayasu Arteritis

79 studies on the registry are indexed under Takayasu Arteritis; 33 are open to participants now.

Browse Takayasu Arteritis studies →

Open to participants now

15 of the 26 studies in Takayasu Arteritis with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Takayasu Arteritis studies recruiting now, 13 (52%) set no upper age limit and 10 (40%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Takayasu Arteritis with a site in China, or all of them as a file.
02

Study summary

  1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
  2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
Read the detailed description

At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

03

Conditions studied

  • Takayasu Arteritis With Pulmonary Artery Involvement
  • Percutaneous Transluminal Pulmonary Angioplasty
  • PAH Targeted Medication

Browse trials for

Keywords

  • Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients diagnosed with Takayasu arteries with pulmonary arteries involvement received either medical or percutaneous transluminal pulmonary angioplasty

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients diagnosed with Takayasu arteries with pulmonary arteries involvement

Exclusion criteria

Exclusion Criteria:

  • Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • DevicePercutaneous transluminal pulmonary angioplasty

    Percutaneous transluminal pulmonary angioplasty

06

What researchers measure

Primary outcomes

  1. all cause death

    all cause death

    Time frame: 2014/1/1-2042/12/31

  2. mean pulmonary arterial pressure change

    change of mean pulmonary arterial pressure after treatment

    Time frame: 2014/1/1-2042/12/31

  3. pulmonary vascular resistance change

    chagne of pulmonary vascular resistance after treatment

    Time frame: 2014/1/1-2042/12/31

  4. 6MWD change

    change of six minute walk distance after treatment

    Time frame: 2014/1/1-2042/12/31

  5. peak VO2 change

    change of peak oxygen consumption after treatment

    Time frame: 2014/1/1-2042/12/31

  6. NT-proBNP change

    change of NT-proBNP after treatment

    Time frame: 2014/1/1-2042/12/31

  7. RV/LV change

    change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment

    Time frame: 2014/1/1-2042/12/31

  8. CI change

    change of cardiac index after treatment

    Time frame: 2014/1/1-2042/12/31

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, China 100000, China
    Recruiting
    • Zhihong Liu, doctor · Contact13269276067
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2014 (actual). Primary completion is estimated for Dec 2042, 347 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 24, 2022
StartActual
Jan 19, 2014
Primary completionEst.
Dec 31, 2042
CompletionEst.
Dec 31, 2042
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05388682
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Jan 19, 2014
Primary completion
Dec 31, 2042 (estimated)
Completion
Dec 31, 2042 (estimated)
Last update
Sep 22, 2026

Study contacts

Zhihong Liu, doctor
Contact
zhihongliufuwai@163.com
86-010-88396589
zhihong Liu, doctor
principal investigator · Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion